(Bloomberg) -- GlaxoSmithKline Plc's Avandia, tainted
by reports linking the drug to increased heart attack risks, may
face a long-term decline in use even if U.S. regulators find the
diabetes pill is safe.
In May, researchers reported that Avandia, Glaxo's second-
biggest revenue producer, may increase chances of heart attacks
by 43 percent. Since then sales have slumped as doctors turn to
other medicines, and shares of London-based Glaxo have dropped 13
percent, wiping out $23 billion of market value.
Read more at Bloomberg Exclusive News
by reports linking the drug to increased heart attack risks, may
face a long-term decline in use even if U.S. regulators find the
diabetes pill is safe.
In May, researchers reported that Avandia, Glaxo's second-
biggest revenue producer, may increase chances of heart attacks
by 43 percent. Since then sales have slumped as doctors turn to
other medicines, and shares of London-based Glaxo have dropped 13
percent, wiping out $23 billion of market value.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment